Clinical validation of a novel, nutritional treatment to induce weight loss in obese volunteers and Type 2 diabetic patients

我们已经证明了一种新的分子途径，通过该途径，双重激活营养物敏感G蛋白偶联受体（GPCR），GPR 84和FFAR 4，导致在人肠道组织样品中协同释放有效的食欲降低激素- PYY和GLP-1。这些激素由肠内分泌细胞储存和释放，特别是主要在下肠（结肠）中发现的L细胞。通过向结肠输送同时激活GPR 84和FFAR 4的营养组合，我们证明了肥胖志愿者中PYY水平的增加导致卡路里摄入量的降低（Peiris等人，Gut，2022）。我们现在要评估我们的减肥策略的有效性。

We have demonstrated a novel molecular pathway by which dual activation nutrient-sensing G-protein coupled receptors (GPCRs), GPR84 and FFAR4, results in synergistic release of potent appetite lowering hormones - PYY and GLP-1, in human gut tissue samples. These hormones are stored and released by enteroendocrine cells, specifically L-cells which are found predominantly in the lower bowel (colon). By delivering our nutrient combination, that simultaneously activates GPR84 and FFAR4, to the colon, we demonstrated increased PYY levels resulting in lower calorific intake, in obese volunteers (Peiris et al, Gut, 2022). We now want to assess the efficacy of our strategy for weight loss.